SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patientcompleted checklist to assess antipsychotic drug side effects

被引:36
作者
Haddad, Peter M. [1 ]
Fleischhacker, W. Wolfgang [2 ]
Peuskens, Joseph [3 ]
Cavallaro, Roberto [4 ]
Lean, Michael E. J. [5 ]
Morozova, Margarita [6 ]
Reynolds, Gavin [7 ]
Azorin, Jean-Michel [8 ]
Thomas, Pierre [9 ]
Moeller, Hans-Juergen [10 ]
机构
[1] Greater Manchester West Mental Hlth NHS Fdn Trust, Cromwell House,Cromwell Rd, Salford M30 OGT, Lancs, England
[2] Med Univ Innsbruck, Innsbruck, Austria
[3] Katholieke Univ Leuven, Kortenberg, Belgium
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Russian Acad Med Sci, Natl Ctr Mental Hlth, Moscow, Russia
[7] Sheffield Hallam Univ, Sheffield, S Yorkshire, England
[8] Hop St Marguerite, Marseille, France
[9] Univ Lille Nord France, Lille, France
[10] Ludwig Maximilians Univ Munchen, Munich, Germany
关键词
antipsychotics; checklist; rating scale; side effects; tolerability;
D O I
10.1177/2045125313510195
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Antipsychotic drug side effects are common and can cause stigmatisation, decreased quality of life, poor adherence, and secondary morbidity and mortality. Systematic assessment of anticipated side effects is recommended as part of good clinical care, but is uncommon in practice and patients may not spontaneously report side effects. We aimed to develop a simple patient-completed checklist to screen systematically for potential antipsychotic side effects. Methods: The SMARTS checklist was developed over a series of group meetings by an international faculty of 12 experts (including psychiatrists, a general physician and a psychopharmacologist) based on their clinical experience and knowledge of the literature. The emphasis is on tolerability (i.e. assessment of side effects that 'trouble' the patient) as subjective impact of side effects is most relevant to medication adherence. The development took account of feedback from practising psychiatrists in Europe, the Middle East and Africa, a process that contributed to face validity. Results: The SMARTS checklist assesses whether patients are currently 'troubled' by 11 well-established potential antipsychotic side effects. Patients provide their responses to these questions by circling relevant side effects. An additional open question enquires about any other possible side effects. The checklist has been translated into Italian and Turkish. Conclusions: The SMARTS checklist aims to strike a balance between brevity and capturing the most common and important antipsychotic side effects. It is appropriate for completion by patients prior to a clinical consultation, for example, in the waiting room. It can then form the focus for a more detailed clinical discussion about side effects. It can be used alone or form part of a more comprehensive assessment of antipsychotic side effects including blood tests and a physical examination when appropriate. The checklist assesses current problems and can be used longitudinally to assess change.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 23 条
[2]  
Barnes T., 2012, SCHIZOPHR RES S1, V136, pS258
[3]   A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].
BARNES, TRE .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676
[4]  
Clinical Standards Board for Scotland, 2001, CLIN STAND SCHIZ
[5]   A SELF-RATING SCALE FOR MEASURING NEUROLEPTIC SIDE-EFFECTS - VALIDATION IN A GROUP OF SCHIZOPHRENIC-PATIENTS [J].
DAY, JC ;
WOOD, G ;
DEWEY, M ;
BENTALL, RP .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 166 :650-653
[6]   Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) [J].
De Hert, M. ;
Dekker, J. M. ;
Wood, D. ;
Kahl, K. G. ;
Holt, R. I. G. ;
Moeller, H. -J. .
EUROPEAN PSYCHIATRY, 2009, 24 (06) :412-424
[7]   Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline [J].
Fakhoury, WKH ;
Wright, D ;
Wallace, M .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (03) :153-162
[8]  
Fleischhacker W Wolfgang, 2009, J Clin Psychiatry, V70, pe06, DOI 10.4088/JCP.7062br1c.e06
[9]  
Guy W., 1976, ECDCEU ASSESSMENT MA
[10]   Adverse effects of atypical antipsychotics: Differential risk and clinical implications [J].
Haddad, Peter M. ;
Sharma, Sonu G. .
CNS DRUGS, 2007, 21 (11) :911-936